Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2026
Journal Article
Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 <scp>ALLG MM23</scp> ( <scp>SeaLAND</scp> ) trial
Rees, Matthew J., Lasica, Masa, Kalff, Anna, Low, Michael, Harrup, Rosemary, Lai, Hock Choong, Sidiqi, M. Hasib, Doo, Nicole Wong, Routledge, David, Hocking, Jay, Campbell, Philip, Heenan, Jessica, Horvath, Noemi, Chien, Nicole, Renwick, William E. P., McCaughan, Georgia, Eek, Richard, Lenton, Douglas S., Wright, Tricia, Gazdar, Sher Gul, Mazumdar, Deepmala, Butcher, Belinda, Mollee, Peter, Quach, Hang and the Australasian Leukaemia and Lymphoma Group (2026). Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 ( SeaLAND ) trial. British Journal of Haematology bjh.70851. doi: 10.1111/bjh.70851
2026
Journal Article
Toxicity‐related treatment cessation in newly diagnosed multiple myeloma—risk factors and survival: an analysis from the APAC and ANZ Myeloma and Related Diseases Registry
Lee, Ji Hyun, Kim, Sung‐Hyun, Kim, Kihyun, Ashrafi, Elham, Wellard, Cameron, Moore, Elizabeth, Chng, Wee Joo, Chen, Wenming, Gan, Gin Gin, Ho, Phoebe Joy, Mollee, Peter, Quach, Hang, Harrison, Simon, McDonald, Emma J. and Spencer, Andrew (2026). Toxicity‐related treatment cessation in newly diagnosed multiple myeloma—risk factors and survival: an analysis from the APAC and ANZ Myeloma and Related Diseases Registry. European Journal of Haematology ejh.70318. doi: 10.1111/ejh.70318
2026
Conference Publication
Relationships Between Quality of Life, Bone Pain, Fatigue and Disease Symptoms, and Physical Activity, Neuromuscular Strength and Fitness, in People With Multiple Myeloma
Nicol, Jennifer L., Chong, Jamie E., Cunningham, Brent, Woodrow, Carmel, King, Tracy, Beck, Belinda, Kay, Shelley, McDonald, Michelle, Carter, Daniel, Beer, Hayley, Mollee, Peter, Weber, Nicholas, Nicol, Andrew, Hill, Michelle, Hart, Nicolas and Skinner, Tina (2026). Relationships Between Quality of Life, Bone Pain, Fatigue and Disease Symptoms, and Physical Activity, Neuromuscular Strength and Fitness, in People With Multiple Myeloma. NEW YORK: ELSEVIER SCIENCE INC.
2026
Journal Article
LBA-16 Relationships Between Quality of Life, Bone Pain, Fatigue and Disease Symptoms, and Physical Activity, Neuromuscular Strength and Fitness, in People With Multiple Myeloma
Nicol, Jennifer L., Chong, Jamie E., Cunningham, Brent, Woodrow, Carmel, King, Tracy, Beck, Belinda, Kay, Shelley, McDonald, Michelle, Carter, Daniel, Beer, Hayley, Mollee, Peter, Weber, Nicholas, Nicol, Andrew, Hill, Michelle, Hart, Nicolas and Skinner, Tina (2026). LBA-16 Relationships Between Quality of Life, Bone Pain, Fatigue and Disease Symptoms, and Physical Activity, Neuromuscular Strength and Fitness, in People With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 26, S381. doi: 10.1016/s2152-2650(26)03942-x
2026
Journal Article
Impact of socioeconomic status on treatment and survival in multiple myeloma in Australia
Gration, Betty, Wellard, Cameron, Moore, Elizabeth, Mollee, Peter, Shetty, Anita, Forsyth, Cecily, Heenan, Jessica, Kerridge, Ian, McQuilten, Zoe, Wood, Erica, Spencer, Andrew and McCaughan, Georgia (2026). Impact of socioeconomic status on treatment and survival in multiple myeloma in Australia. Blood Cancer Journal. doi: 10.1038/s41408-026-01596-7
2026
Journal Article
Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry
Lim, Kenneth J. C., Ashrafi, Elham, Wellard, Cameron, Moore, Elizabeth M., Gration, Betty, Augustson, Bradley, Mollee, Peter, Zhang, Jennifer, Doo, Nicole Wong, Dun, Karen, Cooke, Rachel, Ringkowski, Sabine, Bryant, Adam, McCaughan, Georgia, Wood, Erica, McQuilten, Zoe, Ho, P. Joy, Quach, Hang and Spencer, Andrew (2026). Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry. British Journal of Haematology, 209 (2) bjh.70609, 764-768. doi: 10.1111/bjh.70609
2026
Journal Article
A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma
Lee, Hans C., Plattel, Wouter J., Harrison, Simon J., Sborov, Douglas W., Lentzsch, Suzanne, Spencer, Andrew, Niesvizky, Ruben, Trudel, Suzanne, Mollee, Peter, Vij, Ravi, Minnema, Monique C., Rasche, Leo, Upreti, Vijay V., Zhou, Di, Xia, Qing, Talpes, Mihaela, Eggert, Tobias, Kapoor, Prashant and Ailawadhi, Sikander (2026). A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma. Blood, 148 (2) blood.2025032044, 199-212. doi: 10.1182/blood.2025032044
2026
Journal Article
An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy
Gibbons, Anthea, Chakravorty, Lipi, Sidiqi, Hasib, Ting, Stephen, Kwok, Fiona, Wisniowski, Brendan, Ranjit Anderson, Nirija, Korczyk, Dariusz, Motorna, Olga and Mollee, Peter (2026). An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy. Internal Medicine Journal, 56 (4) imj.70335, 582-588. doi: 10.1111/imj.70335
2026
Journal Article
An individualised exercise intervention improves health outcomes for people with multiple myeloma: The Myeex randomised waitlist-controlled trial
Skinner, Tina, Nicol, Jenny, Cunningham, Brent, Woodrow, Carmel, Adlard, Kirsten, Mollee, Peter, Weber, Nicholas, Robinson, Harley, Okano, Satomi, Stoll, Thomas, Hartel, Gunter, Nicol, Andrew and Hill, Michelle (2026). An individualised exercise intervention improves health outcomes for people with multiple myeloma: The Myeex randomised waitlist-controlled trial. Journal of Clinical Exercise Physiology, 15 (s2), 252-252. doi: 10.31189/2165-7629-15-s2.252
2026
Journal Article
Cytogenetic testing in newly diagnosed multiple myeloma: real world evidence on clinical features and adverse outcomes for high risk groups
Zammar, Ghassan, Augustson, Bradley, Moore, Elizabeth, Wellard, Cameron, Ashrafi, Elham, Sidiqi, Hasib, Lim, Kenneth J. C., Radeski, Dejan, Jackson, Alannah, Bergin, Krystal, Harrison, Simon, Ho, P Joy, King, Tracy, Quach, Hang, Mollee, Peter, Rajagopal, Rajeev, Rosengarten, Brian, Wood, Erica, McQuilten, Zoe and Spencer, Andrew (2026). Cytogenetic testing in newly diagnosed multiple myeloma: real world evidence on clinical features and adverse outcomes for high risk groups. Clinical Lymphoma Myeloma and Leukemia, 26 (4), e492-e501.e1. doi: 10.1016/j.clml.2025.12.005
2026
Journal Article
Comparative evaluation of free light chain assays in AL amyloidosis: performance of Sebia versus Freelite and N-Latex
Zhao, Frances, Pretorius, Carel and Mollee, Peter (2026). Comparative evaluation of free light chain assays in AL amyloidosis: performance of Sebia versus Freelite and N-Latex. Practical Laboratory Medicine, 49 e00519, 1-7. doi: 10.1016/j.plabm.2026.e00519
2026
Journal Article
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Sim, Shirlene, McCaughan, Georgia, Zannettino, Andrew, Ho, P. Joy, Joshua, Douglas, Talaulikar, Dipti, Mollee, Peter, Prince, H. Miles, Spencer, Andrew, Harrison, Simon, Lee, Cindy, Augustson, Bradley, Kalff, Anna, Ling, Silvia, Weber, Nicholas, Yong, Angelina and Quach, Hang (2026). Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 56 (3) imj.70329, 457-464. doi: 10.1111/imj.70329
2026
Journal Article
Wild-type transthyretin-related amyloidosis in kindreds: a play of chance or new epiphenomenon?
Kang, Katherine, Mollee, Peter, Booth, David and Korczyk, Dariusz (2026). Wild-type transthyretin-related amyloidosis in kindreds: a play of chance or new epiphenomenon?. Heart, Lung and Circulation, 35 (3). doi: 10.1016/j.hlc.2025.06.1038
2026
Journal Article
Real-world comparison of treatment outcomes for multiple myeloma in elderly transplant ineligible patients receiving first-line VRd, Rd and VCd: Results from the Australian and New Zealand Myeloma and Related Diseases Registry
Zhao, Sarah, Wellard, Cameron, Moore, Elizabeth M., Spencer, Andrew, Quach, Hang, Ho, P. Joy, McDonald, Emma-Jane, Mollee, Peter, Harrison, Simon J., Augustson, Bradley, Wood, Erica M., McQuilten, Zoe K. and Rajagopal, Rajeev (2026). Real-world comparison of treatment outcomes for multiple myeloma in elderly transplant ineligible patients receiving first-line VRd, Rd and VCd: Results from the Australian and New Zealand Myeloma and Related Diseases Registry. Clinical Lymphoma Myeloma and Leukemia, 26 (1), 49-56. doi: 10.1016/j.clml.2025.08.004
2026
Journal Article
A post-market economic evaluation of bortezomib, lenalidomide and dexamethasone versus pre-funding standard of care for newly diagnosed multiple myeloma using registry data
Irving, Adam, Petrie, Dennis, Harris, Anthony, Fanning, Laura, Wood, Erica M., Moore, Elizabeth, Wellard, Cameron, Waters, Neil, Augustson, Bradley, Cook, Gordon, Gay, Francesca, McCaughan, Georgia, Mollee, Peter, Spencer, Andrew and McQuilten, Zoe K. (2026). A post-market economic evaluation of bortezomib, lenalidomide and dexamethasone versus pre-funding standard of care for newly diagnosed multiple myeloma using registry data. PharmacoEconomics, 44 (1), 83-95. doi: 10.1007/s40273-025-01554-4
2025
Conference Publication
Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups
Zammar, Ghassan, Augustson, Bradley, Moore, Elizabeth, Sidiqi, M Hasib, Wellard, Cameron, Ashrafi, Elham, Harrison, Simon, Radeski, Dejan, Jackson, Alannah, Bergin, Krystal, Ho, Phoebe Joy, King, Tracy, Mollee, Peter, Quach, Hang, Rajagopal, Rajeev, McQuilten, Zoe, Wood, Erica, Rosengarten, Brian and Spencer, Andrew (2025). Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups. 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-2221
2025
Conference Publication
Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)
Lim, Sueh-Li, Reynolds, John, Pemberton, Lucy, Wright, Tricia, Lee, Sophie, Mollee, Peter, Shetty, Anita C., Kim, Yu Jin, Helen, Weston, Nina, Byard, Le, Khoa, McQuilten, Zoe, Quach, Hang and Spencer, Andrew (2025). Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22). 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-5842
2025
Conference Publication
Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis
Chakraborty, Rajshekhar, Kastritis, Efstathios, Huart, Antoine, Jaccard, Arnaud, Landau, Heather, Iida, Shinsuke, Motorna, Olga, Mollee, Peter, Ishida, Tadao, Kawano, Yawara, Bhutani, Manisha, D'Souza, Anita, Cowan, Andrew, Hoffman, James, Talati, Chetasi, Rosenberg, Tanya, La Motte-Mohs, Ross, Wang, Fan, Hoffman, David, Fei, Mingwei, Arriola, Emma, Yu, Jovian, Kumar, Shaji, Dispenzieri, Angela, Palladini, Giovanni and Sanchorawala, Vaishali (2025). Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis. 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-692
2025
Conference Publication
Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)
Rees, Matthew, Lasica, Masa, Kalff, Anna, Low, Michael, Harrup, Rosemary, Lai, Hock Choong, Sidiqi, M Hasib, Wong Doo, Nicole, Routledge, David, Hocking, Jay, Campbell, Philip, Heenan, Jessica, Horvath, Noemi, Chien, Nicole, Renwick, William, McCaughan, Georgia, Eek, Richard, Lenton, Douglas, Gazdar, Sher Gul, Mazumdar, Deepmala, Butcher, Belinda, Mollee, Peter and Quach, Hang (2025). Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND). 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-4039
2025
Journal Article
A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis
Sanchorawala, Vaishali, Wechalekar, Ashutosh, Mollee, Peter, Sekijima, Yoshiki, Maurer, Mathew S., Leung, Nelson, Schönland, Stefan O. and Kumar, Shaji (2025). A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis. Amyloid, 32 (4), 1-6. doi: 10.1080/13506129.2025.2570096
Funding
Past funding
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Master Philosophy
Frailty assessment in patients with multiple myeloma
Principal Advisor
Other advisors: Professor Ruth Hubbard
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: